Achmea Investment Management B.V. cut its holdings in shares of Zoetis Inc (NYSE:ZTS) by 21.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 66,747 shares of the company’s stock after selling 18,195 shares during the quarter. Achmea Investment Management B.V.’s holdings in Zoetis were worth $6,108,000 as of its most recent SEC filing.
Several other hedge funds have also modified their holdings of the company. Polen Capital Management LLC lifted its holdings in shares of Zoetis by 3.9% during the second quarter. Polen Capital Management LLC now owns 9,295,080 shares of the company’s stock worth $791,848,000 after buying an additional 351,447 shares during the last quarter. Massachusetts Financial Services Co. MA lifted its holdings in shares of Zoetis by 1.6% during the third quarter. Massachusetts Financial Services Co. MA now owns 7,692,247 shares of the company’s stock worth $704,302,000 after buying an additional 119,154 shares during the last quarter. Wells Fargo & Company MN lifted its holdings in shares of Zoetis by 9.1% during the second quarter. Wells Fargo & Company MN now owns 6,375,146 shares of the company’s stock worth $543,099,000 after buying an additional 529,666 shares during the last quarter. Janus Henderson Group PLC lifted its holdings in shares of Zoetis by 22.3% during the second quarter. Janus Henderson Group PLC now owns 5,410,040 shares of the company’s stock worth $460,890,000 after buying an additional 985,586 shares during the last quarter. Finally, Bank of New York Mellon Corp lifted its holdings in shares of Zoetis by 8.7% during the second quarter. Bank of New York Mellon Corp now owns 5,262,461 shares of the company’s stock worth $448,309,000 after buying an additional 422,856 shares during the last quarter. Institutional investors own 89.68% of the company’s stock.
Shares of NYSE ZTS opened at $95.27 on Friday. The company has a debt-to-equity ratio of 3.04, a current ratio of 4.06 and a quick ratio of 2.63. The firm has a market capitalization of $44.57 billion, a P/E ratio of 39.70, a PEG ratio of 1.83 and a beta of 0.97. Zoetis Inc has a one year low of $68.56 and a one year high of $96.57.
The company also recently announced a quarterly dividend, which will be paid on Monday, December 3rd. Investors of record on Tuesday, November 20th will be paid a $0.126 dividend. The ex-dividend date is Monday, November 19th. This represents a $0.50 dividend on an annualized basis and a dividend yield of 0.53%. Zoetis’s payout ratio is 20.83%.
In other Zoetis news, CEO Juan Ramon Alaix sold 135,000 shares of the stock in a transaction on Tuesday, August 14th. The stock was sold at an average price of $91.55, for a total transaction of $12,359,250.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Catherine A. Knupp sold 46,816 shares of the stock in a transaction on Wednesday, August 15th. The stock was sold at an average price of $90.84, for a total value of $4,252,765.44. Following the transaction, the insider now owns 81,640 shares of the company’s stock, valued at $7,416,177.60. The disclosure for this sale can be found here. Insiders have sold 350,507 shares of company stock valued at $32,579,830 over the last quarter. Corporate insiders own 0.35% of the company’s stock.
A number of research analysts have recently commented on ZTS shares. Stifel Nicolaus upped their price target on Zoetis from $86.00 to $95.00 and gave the stock a “buy” rating in a report on Friday, August 3rd. Morgan Stanley upped their price target on Zoetis from $87.00 to $92.00 and gave the stock a “hold” rating in a report on Friday, August 3rd. Cantor Fitzgerald set a $98.00 price target on Zoetis and gave the stock a “buy” rating in a report on Friday, July 27th. JPMorgan Chase & Co. upped their target price on Zoetis from $100.00 to $101.00 and gave the company an “overweight” rating in a research note on Friday, November 2nd. Finally, Jefferies Financial Group set a $96.00 target price on Zoetis and gave the company a “buy” rating in a research note on Friday, July 13th. Seven investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $93.19.
COPYRIGHT VIOLATION NOTICE: “Zoetis Inc (ZTS) Shares Sold by Achmea Investment Management B.V.” was published by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this story on another website, it was illegally stolen and republished in violation of US & international copyright and trademark law. The correct version of this story can be read at https://sportsperspectives.com/2018/11/10/zoetis-inc-zts-shares-sold-by-achmea-investment-management-b-v.html.
Zoetis Company Profile
Zoetis, Inc discovers, develops and manufactures a portfolio of animal health medicines and vaccines. Its products are complemented by diagnostic products, genetic tests, bio devices and services. These are designed to meet the needs of veterinarians and the livestock farmers and companion animal. The firm provides its services though five categories namely, anti-invectives, vaccines, parasitic ides, medicated feed additives, and other pharmaceuticals.
Read More: New Google Finance Tool and Screening Stocks
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc (NYSE:ZTS).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.